Differing anti-proteinuric action of candesartan and losartan in chronic renal disease

Hypertension Research

Volumn 26, Issue 11, 2003, Pages 875-880

  Matsuda, Hiroto ^a,b   Hayashi, Koichi ^b   Homma, Koichiro ^b   Yoshioka, Kyoko ^b   Kanda, Takeshi ^b   Takamatsu, Ichiro ^b   Tatematsu, Satoru ^b   Wakino, Shu ^b   Saruta, Takao ^b  

^a ASHIKAGA RED CROSS HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blockers; Candesartan; Chronic renal disease; Losartan; Nitric oxide

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CREATININE; DILAZEP; DIPYRIDAMOLE; LOSARTAN; NITRIC OXIDE; PERINDOPRIL; TRANDOLAPRIL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTECTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BLOOD PRESSURE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; NITRIC OXIDE; PERINDOPRIL; PROTEINURIA; TETRAZOLES;

EID: 0345530947     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.875     Document Type: Article

References (32)

1. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000.
2. Taguma Y, Kitamoto Y, Futaki G, et al: Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617-1620.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 326: 1456-1462.
4. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, AIPRI Study Group: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945.
5. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
6. Lewis EJ, Hunsicker LG, Clarke WR, et al, Collaborative Study Group: Renoprotective effect of the angiotensin-receptor blocker irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
7. Fabiani ME, Dinh DT, Nassis L, Casley DJ, Johnston CI: In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan. Am J Hypertens 2000; 13: 1005-1013.
8. Ojima M, Inada Y, Shibouta Y, et al: Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997; 319: 137-146.
9. Hansson L: The relationship between dose and antihypertensive effect for different AT1-receptor blockers. Blood Press 2001; 10(Suppl 3): 33-39.
10. Liu Y-H, Yang X-P, Sharov VG, et al: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926-1935.
11. Siragy HM, de Gasparo M, Carey RM: Angiotensin type 2 receptor mediates valsartan-induced hypotension in' conscious rats. Hypertension 2000; 35: 1074-1077.
12. Siragy HM, Jaffa AA, Margolius HS, Carey RM: Renin-angiotensin system modulates renal bradykinin production. Am J Physiol 1996; 271: R1090-R1095.
13. Kon V, Fogo A, Ichikawa I: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545-550.
14. Matsuda H, Hayashi K, Arakawa K, et al: Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol 1999; 10: 2272-2282.
15. Ohta K, Araki N, Shibata M, et al: A novel in vivo assay system for consecutive measurement of brain nitric oxide production combined with the microdialysis technique. Neurosci Lett 1994; 176: 165-168.
16. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1996; 349: 1857-1863.
17. Wright JT Jr, Agodoa L, Contreras G, et al: African American Study of Kidney Disease and Hypertension Study Group: successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162: 1636-1643.
18. Kuriyama S, Tomonari H, Tokudome G, et al: Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 2003; 25: 849-855.
19. Gradman AH: AT1-receptor blockers: differences that matter. J Hum Hypertens 2002; 16: S9-S16.
20. Unger T: Pharmacology of AT1-receptor blockers. Blood Press 2001; 10 (Suppl 3): 5-10.
21. Carey RM, Jin X, Wang Z, Siragy HM: Nitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor. Acta Physiol Scand 2000; 168: 65-71.
22. Lacourciere Y, Asmar R: A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study: Candesartan/Losartan study investigators. Am J Hypertens 1999; 12: 1181-1187.
23. Sato A, Suzuki Y, Shibata H, Saruta T: Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res 2000; 23: 25-31.
24. Sosa-Canache B, Cierco M, Gutierrez CI, Israel A: Role of bradykinin and nitric oxide in the AT2 receptor-mediated hypotension. J Hum Hypertens 2000; 14: S40-S46.
25. Siragy HM, de Gasparo M, Carey RM: Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000; 35: 1074-1077.
26. Weir MR, Henrich WL: Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens 2000; 9: 403-411.
27. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T: Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40: 521-527.
28. Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H: Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion. BMC Nephrol 2002; 3: 2.
29. Rahma M, Kimura S, Yoneyama H, et al: Effects of furosemide on the tubular reabsorption of nitrates in anesthetized dogs. Eur J Pharmacol 2001; 428: 113-119.
30. Kang DH, Nakagawa T, Feng L, Johnson RJ: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 2002; 161: 239-248.
31. Rangan GK, Wang Y, Harris DC: Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J Am Soc Nephrol 2001; 12: 1696-1705.
32. Edwards RM: Response of isolated renal arterioles to acetylcholine, dopamine, and bradykinin. Am J Physiol 1985; 248: F183-F189.